GLP-1NCT06094894
Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1
A study testing sucralose in people with GLP-1 and Gut Microbiota, run by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran at 1 site in Mexico.
Trial summary
Recently, it has been proposed that the consumption of non-nutritive sweeteners, including sucralose, it's not harmless and is related with metabolic effects. Some studies have reported that sucralose produces alterations in glucose homeostasis. Read more about this study
- Who is it for?
- Ages 20 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- GLP-1, Gut Microbiota, Insulin Resistance
- What is being tested?
- sucralose
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteMexico
- Study dates
- 1 Jun 2023to 1 Mar 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Normal BMI (18.5-24.9 kg/m2)
- Low habitual consumption of non-nutritive sweeteners (NNS
- Fasting plasma insulin concentration of <12 mU/L
Who cannot join
- Diabetes or altered glucose metabolism (abnormal fasting glucose, glucose intolerance or elevated glycated hemoglobin)
- Use of antibiotics in the last 3 months
- Use of probiotics through pharmaceutical products
- Liver or kidney disease
- Use of medications that could interfere with insulin sensitivity
- Severe intestinal diseases
- History of bariatric surgery
- Pregnancy or lactation
Trial locations and contacts
1 site in 1 country.
Mexico1 site
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico City, 14080
About this study
Official title: Changes in Gut Microbiota and Postprandial GLP-1 Concentration Due to Sucralose Consumption
Recently, it has been proposed that the consumption of non-nutritive sweeteners, including sucralose, it's not harmless and is related with metabolic effects. Some studies have reported that sucralose produces alterations in glucose homeostasis. In vitro studies indicate that sucralose can interact with sweet taste receptors (T1R2 and T1R3) in the intestine, thus increasing the expression of glucose transporters including the sodium-glucose cotransporter type 1 (SGLT1) and the glucose transporter 2 (GLUT2), increasing glucose absorption. This interaction with intestinal sweet taste receptors also generates an increase in the secretion of the incretins glucagon-like peptide type 1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), which might enhance the postprandial insulin release. However, these results are preliminary and it's desirable to confirm if sucralose consumption is associated with glucose metabolism modifications using an appropriate methodological design and with gold standard methods. The aim of this triple-blind, placebo-controlled, parallel, randomized clinical trial is to confirm the changes in insulin sensitivity associated with sucralose consumption in humans, to identify whether these changes are in the liver or skeletal muscle and to investigate the pathophysiological mechanisms generating these changes. Specifically, we will investigate if sucralose generates a dysbiosis in the gut microbiota that could be related to insulin resistance by increasing concentrations of lipopolysaccharide, a toxin found in Gram-negative bacteria that triggers a low-grade inflammation known as metabolic endotoxemia. In addition, the changes in postprandial concentrations of GLP-1, glucose, insulin, and C-peptide due to the combination of sucralose with a mixed meal will be investigated. The results of this study will determine if sucralose consumption, frequently used as a non-nutritive sweetener, is associated to significant changes in glucose homeostasis in humans.
Read the detailed description
Study design:
This is a triple-blind, parallel, placebo-controlled, randomized clinical trial.
Sample size:
The sample size was calculated to observe a difference of 20% in the Matsuda index between groups.
The calculation was done considering a probability of type I error (α) of 5%, with a power of 80% and adding an extra-20% for potential losses at follow-up.
The estimated sample size for the study is 40 subjects, 20 per group.
Randomization:
The participants will be randomly assigned to one of the two groups (sucralose or placebo) using the website Randomization.com (http://www.randomization.com) with a balanced block design of 5 blocks with 8 subjects each. The random allocation sequence will be done by an external researcher.
Intervention:
The intervention will consist of capsules filled with pure sucralose or placebo (cornstarch) accordingly to the group assignment. Each capsule will contain 90 mg of sucralose or placebo. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose or placebo, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
The use of identical capsules will allow the blinding, the capsules will be deposited in bottles numbered sequentially according to the enrollment process and neither the participants nor the researches will know the content of the capsules or the group assigned.
Visit 1
An oral glucose tolerance test (OGTT) will be performed to confirm that participants do not have diabetes or prediabetes. Fasting insulin, lipid profile and glycated hemoglobin will be measured. Also, anthropometry (weight, height, waist, and hip circumference), blood pressure and heart rate will be documented. Body composition will be evaluated with dual X-ray absorptiometry (DXA) already available in the Research Unit and bioelectrical impedance. Physical activity will be registered with the questionnaire from the University of Laval that measure energy expenditure in Kcal per day. A format for three-day food intake record will be given to be prospectively registered by participants.
Visit 2
The three-day food record will be requested and reviewed to evaluate food consumption habits. A mixed meal tolerance test will be performed over two hours. The meal will consist of 523 kcal (49% carbohydrates, 17% protein, 34% lipids). Blood samples will be collected at 0, 30, 60, 90 and 120 minutes to measure glucose, insulin and glucagon-like peptide type 1 (GLP-1) concentrations. Also, lipopolysaccharide (LPS), C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α) concentrations will be measured at the basal time. Ten minutes before the test participants will consume a capsule containing either sucralose or placebo (120 mg).
Participants will proportionate the first stool sample to evaluate gut microbiota.
The researchers will proportionate the bottle with capsules that each participant will consume during the intervention period (30 ± 2 days) in this visit. Also, each participant will be asked to record on the adherence format if they consumed the capsule at breakfast, lunch, and dinner each day of the intervention period and to record any symptom related to capsules ingestion. Another format to record three-day food consumption again will be given.
Visit 3
Participants will proportionate the second stool sample to evaluate changes in gut microbiota. Also, the physical activity questionnaire will be applied again, and the second 3-day food record will be obtained to evaluate changes in physical activity and food habits, respectively. The second mixed meal tolerance test will be performed following the same procedures as visit 2. Participants will be asked to return the empty bottles to quantify adherence to the intervention. In addition, adherence and symptoms formats will be collected.
Visit 4
Participants will be asked to assist one month after visit 3 to make a final evaluation of fasting glucose, insulin, and lipid profile concentrations. The physical activity questionnaire will be applied again, and a third 3-day food record will be collected to evaluate changes in physical activity and food habits, respectively.
- Conditions
- GLP-1, Gut Microbiota, Insulin Resistance
- Being tested
- sucralose, placebo
- Keywords
- incretins, gut microbiota, sucralose, insulin resistance
- Medical subject headings
- Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
sucraloseOther
Also called non-nutritive sweetener
Food additive used to replace sugar providing a sweet taste without calories.
placeboOther
Cornstarch without significant physiological effects
| Study group | Role | What they receive |
|---|---|---|
| Sucralose | Experimental | The intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose. Receives: Other: sucralose |
| Placebo | Placebo comparator | The intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group. Receives: Other: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
glucose
To evaluate the changes in postprandial glucose concentrations during a mixed meal after sucralose consumption in comparison to placebo
Measured: baseline and 30 days after the intervention
insulin
To evaluate the changes in postprandial insulin concentrations during a mixed meal after sucralose consumption in comparison to placebo
Measured: baseline and 30 days after the intervention
C-peptide
To evaluate the changes in postprandial C-peptide concentrations during a mixed meal after sucralose consumption in comparison to placebo
Measured: baseline and 30 days after the intervention
GLP-1
To evaluate the changes in postprandial GLP-1 area under the curve during a mixed meal after sucralose consumption in comparison to placebo
Measured: baseline and 30 days after the intervention
gut microbiota
To compare the change in the relative abundance of colony forming units of bacterial genus and species after sucralose consumption in comparison to placebo through messenger RNA sequencing
Measured: baseline and 30 days after the intervention
PYY
To evaluate the changes in postprandial PYY area under the curve during a mixed meal after sucralose consumption in comparison to placebo
Measured: baseline and 30 days after the intervention
ghrelin
To evaluate the changes in postprandial ghrelin area under the curve during a mixed meal after sucralose consumption in comparison to placebo
Measured: baseline and 30 days after the intervention
Secondary outcomes (4)
lipopolysaccharide
To determine the effects of sucralose consumption in lipopolysaccharide concentrations in comparison to placebo
Measured: baseline and 30 days after the intervention
C-reactive protein
To determine the effects of sucralose consumption in C-reactive protein concentrations in comparison to placebo
Measured: baseline and 30 days after the intervention
IL-6
To determine the effects of sucralose consumption in IL-6 concentrations in comparison to placebo
Measured: baseline and 30 days after the intervention
tumor necrosis factor-alpha
To determine the effects of sucralose consumption in tumor necrosis factor-alpha concentrations in comparison to placebo
Measured: baseline and 30 days after the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Oct 2023
- Study start1 Jun 2023
- Primary completion29 Feb 2024
- Study completion1 Mar 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (9)Papers the sponsor has linked to this study.
- Other trials for GLP-1Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Triple blind parallel placebo-controlled randomized clinical trial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Paloma Almeda-Valdés, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06094894
- Sponsor's protocol ID
- 2635.2
- Status last verified
- Apr 2025
- First submitted
- 17 Oct 2023
- Last updated
- 4 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care. 2013 Sep;36(9):2530-5. doi: 10.2337/dc12-2221. Epub 2013 Apr 30.
PubMed 23633524Romo-Romo A, Aguilar-Salinas CA, Gomez-Diaz RA, Brito-Cordova GX, Gomez-Velasco DV, Lopez-Rocha MJ, Almeda-Valdes P. Non-Nutritive Sweeteners: Evidence on their Association with Metabolic Diseases and Potential Effects on Glucose Metabolism and Appetite. Rev Invest Clin. 2017 May-Jun;69(3):129-138. doi: 10.24875/ric.17002141.
PubMed 28613282Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal E, Elinav E. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct 9;514(7521):181-6. doi: 10.1038/nature13793. Epub 2014 Sep 17.
PubMed 25231862Romo-Romo A, Aguilar-Salinas CA, Brito-Cordova GX, Gomez-Diaz RA, Almeda-Valdes P. Sucralose decreases insulin sensitivity in healthy subjects: a randomized controlled trial. Am J Clin Nutr. 2018 Sep 1;108(3):485-491. doi: 10.1093/ajcn/nqy152.
PubMed 30535090Lertrit A, Srimachai S, Saetung S, Chanprasertyothin S, Chailurkit LO, Areevut C, Katekao P, Ongphiphadhanakul B, Sriphrapradang C. Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial. Nutrition. 2018 Nov;55-56:125-130. doi: 10.1016/j.nut.2018.04.001. Epub 2018 Apr 21.
PubMed 30005329Dalenberg JR, Patel BP, Denis R, Veldhuizen MG, Nakamura Y, Vinke PC, Luquet S, Small DM. Short-Term Consumption of Sucralose with, but Not without, Carbohydrate Impairs Neural and Metabolic Sensitivity to Sugar in Humans. Cell Metab. 2020 Mar 3;31(3):493-502.e7. doi: 10.1016/j.cmet.2020.01.014.
PubMed 32130881Suez J, Cohen Y, Valdes-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Linevsky R, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, Stein-Thoeringer CK, Segal E, Elinav E. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022 Sep 1;185(18):3307-3328.e19. doi: 10.1016/j.cell.2022.07.016. Epub 2022 Aug 19.
PubMed 35987213Bueno-Hernandez N, Esquivel-Velazquez M, Alcantara-Suarez R, Gomez-Arauz AY, Espinosa-Flores AJ, de Leon-Barrera KL, Mendoza-Martinez VM, Sanchez Medina GA, Leon-Hernandez M, Ruiz-Barranco A, Escobedo G, Melendez G. Chronic sucralose consumption induces elevation of serum insulin in young healthy adults: a randomized, double blind, controlled trial. Nutr J. 2020 Apr 13;19(1):32. doi: 10.1186/s12937-020-00549-5.
PubMed 32284053Romo-Romo A, Sanchez-Tapia M, Lopez-Carrasco MG, Guillen-Pineda LE, Brito-Cordova GX, Martagon AJ, Granados-Portillo O, Walther G, Gomez-Perez FJ, Aguilar-Salinas CA, Tovar AR, Torres N, Almeda-Valdes P. Sucralose consumption modifies glucose homeostasis, gut microbiota, Curli protein, and related metabolites in healthy individuals: A randomized placebo-controlled, triple-blind trial. Clin Nutr ESPEN. 2025 Oct;69:733-744. doi: 10.1016/j.clnesp.2025.08.029. Epub 2025 Sep 2.
PubMed 40907790
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Changes in Gut Microbiota and Postprandial GLP-1 Concentration Due to Sucralose Consumption
- ClinicalTrials.gov ID
- NCT06094894
- Acronym / sponsor ID
- 2635.2
- Conditions
- GLP-1, Gut Microbiota, Insulin Resistance
- Keywords
- incretins, gut microbiota, sucralose, insulin resistance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUniversity, hospital or other
- Study start
- 1 Jun 2023 (actual)
- Primary completion
- 29 Feb 2024 (actual)
- Study completion
- 1 Mar 2024 (actual)
- First posted
- 23 Oct 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Recently, it has been proposed that the consumption of non-nutritive sweeteners, including sucralose, it's not harmless and is related with metabolic effects. Some studies have reported that sucralose produces alterations in glucose homeostasis. In vitro studies indicate that sucralose can interact with sweet taste receptors (T1R2 and T1R3) in the intestine, thus increasing the expression of glucose transporters including the sodium-glucose cotransporter type 1 (SGLT1) and the glucose transporter 2 (GLUT2), increasing glucose absorption. This interaction with intestinal sweet taste receptors also generates an increase in the secretion of the incretins glucagon-like peptide type 1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), which might enhance the postprandial insulin release. However, these results are preliminary and it's desirable to confirm if sucralose consumption is associated with glucose metabolism modifications using an appropriate methodological design and with gold standard methods. The aim of this triple-blind, placebo-controlled, parallel, randomized clinical trial is to confirm the changes in insulin sensitivity associated with sucralose consumption in humans, to identify whether these changes are in the liver or skeletal muscle and to investigate the pathophysiological mechanisms generating these changes. Specifically, we will investigate if sucralose generates a dysbiosis in the gut microbiota that could be related to insulin resistance by increasing concentrations of lipopolysaccharide, a toxin found in Gram-negative bacteria that triggers a low-grade inflammation known as metabolic endotoxemia. In addition, the changes in postprandial concentrations of GLP-1, glucose, insulin, and C-peptide due to the combination of sucralose with a mixed meal will be investigated. The results of this study will determine if sucralose consumption, frequently used as a non-nutritive sweetener, is associated to significant changes in glucose homeostasis in humans.
Detailed description
Study design:
This is a triple-blind, parallel, placebo-controlled, randomized clinical trial.
Sample size:
The sample size was calculated to observe a difference of 20% in the Matsuda index between groups.
The calculation was done considering a probability of type I error (α) of 5%, with a power of 80% and adding an extra-20% for potential losses at follow-up.
The estimated sample size for the study is 40 subjects, 20 per group.
Randomization:
The participants will be randomly assigned to one of the two groups (sucralose or placebo) using the website Randomization.com (http://www.randomization.com) with a balanced block design of 5 blocks with 8 subjects each. The random allocation sequence will be done by an external researcher.
Intervention:
The intervention will consist of capsules filled with pure sucralose or placebo (cornstarch) accordingly to the group assignment. Each capsule will contain 90 mg of sucralose or placebo. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of sucralose or placebo, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint Food and Agriculture Organization of the United Nations (FAO)/World Health Organization (WHO) expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose.
The use of identical capsules will allow the blinding, the capsules will be deposited in bottles numbered sequentially according to the enrollment process and neither the participants nor the researches will know the content of the capsules or the group assigned.
Visit 1
An oral glucose tolerance test (OGTT) will be performed to confirm that participants do not have diabetes or prediabetes. Fasting insulin, lipid profile and glycated hemoglobin will be measured. Also, anthropometry (weight, height, waist, and hip circumference), blood pressure and heart rate will be documented. Body composition will be evaluated with dual X-ray absorptiometry (DXA) already available in the Research Unit and bioelectrical impedance. Physical activity will be registered with the questionnaire from the University of Laval that measure energy expenditure in Kcal per day. A format for three-day food intake record will be given to be prospectively registered by participants.
Visit 2
The three-day food record will be requested and reviewed to evaluate food consumption habits. A mixed meal tolerance test will be performed over two hours. The meal will consist of 523 kcal (49% carbohydrates, 17% protein, 34% lipids). Blood samples will be collected at 0, 30, 60, 90 and 120 minutes to measure glucose, insulin and glucagon-like peptide type 1 (GLP-1) concentrations. Also, lipopolysaccharide (LPS), C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-α) concentrations will be measured at the basal time. Ten minutes before the test participants will consume a capsule containing either sucralose or placebo (120 mg).
Participants will proportionate the first stool sample to evaluate gut microbiota.
The researchers will proportionate the bottle with capsules that each participant will consume during the intervention period (30 ± 2 days) in this visit. Also, each participant will be asked to record on the adherence format if they consumed the capsule at breakfast, lunch, and dinner each day of the intervention period and to record any symptom related to capsules ingestion. Another format to record three-day food consumption again will be given.
Visit 3
Participants will proportionate the second stool sample to evaluate changes in gut microbiota. Also, the physical activity questionnaire will be applied again, and the second 3-day food record will be obtained to evaluate changes in physical activity and food habits, respectively. The second mixed meal tolerance test will be performed following the same procedures as visit 2. Participants will be asked to return the empty bottles to quantify adherence to the intervention. In addition, adherence and symptoms formats will be collected.
Visit 4
Participants will be asked to assist one month after visit 3 to make a final evaluation of fasting glucose, insulin, and lipid profile concentrations. The physical activity questionnaire will be applied again, and a third 3-day food record will be collected to evaluate changes in physical activity and food habits, respectively.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Triple blind parallel placebo-controlled randomized clinical trial
| Arm | Type | Receives |
|---|---|---|
| Sucralose | Experimental | Other: sucraloseThe intervention will consist of capsules filled with pure sucralose. Each capsule will contain 90 mg of sucralose. Participants will be asked to consume one capsule in each meal (three per day) to achieve an ingestion of 270 mg of sucralose, this quantity corresponds approximately to the 30% of the acceptable daily intake (ADI) of sucralose for a lean person. This was calculated based on the ADI established by the joint FAO/WHO expert committee on food additives (JECFA) of 15 mg per kg of body weight per day of sucralose. |
| Placebo | Placebo comparator | Other: placeboThe intervention will consist of capsules filled with placebo (cornstarch). Each capsule will contain 90 mg of cornstarch. Participants will be asked to consume one capsule in each meal (three per day) in order to achieve an ingestion of 270 mg of placebo, this quantity is in order to match the sucralose consumed in the intervention group. |
Who may qualify
- Ages
- 20 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Normal BMI (18.5-24.9 kg/m2)
- Low habitual consumption of non-nutritive sweeteners (NNS
- Fasting plasma insulin concentration of <12 mU/L
Key exclusion criteria (8 listed)
- Diabetes or altered glucose metabolism (abnormal fasting glucose, glucose intolerance or elevated glycated hemoglobin)
- Use of antibiotics in the last 3 months
- Use of probiotics through pharmaceutical products
- Liver or kidney disease
- Use of medications that could interfere with insulin sensitivity
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| sucraloseAlso: non-nutritive sweetenerFood additive used to replace sugar providing a sweet taste without calories. | Other | Sucralose |
| placeboCornstarch without significant physiological effects | Other | Placebo |
Primary outcome
glucose
Time frame: baseline and 30 days after the intervention
To evaluate the changes in postprandial glucose concentrations during a mixed meal after sucralose consumption in comparison to placebo
insulin
Time frame: baseline and 30 days after the intervention
To evaluate the changes in postprandial insulin concentrations during a mixed meal after sucralose consumption in comparison to placebo
C-peptide
Time frame: baseline and 30 days after the intervention
To evaluate the changes in postprandial C-peptide concentrations during a mixed meal after sucralose consumption in comparison to placebo
GLP-1
Time frame: baseline and 30 days after the intervention
To evaluate the changes in postprandial GLP-1 area under the curve during a mixed meal after sucralose consumption in comparison to placebo
gut microbiota
Time frame: baseline and 30 days after the intervention
To compare the change in the relative abundance of colony forming units of bacterial genus and species after sucralose consumption in comparison to placebo through messenger RNA sequencing
PYY
Time frame: baseline and 30 days after the intervention
To evaluate the changes in postprandial PYY area under the curve during a mixed meal after sucralose consumption in comparison to placebo
ghrelin
Time frame: baseline and 30 days after the intervention
To evaluate the changes in postprandial ghrelin area under the curve during a mixed meal after sucralose consumption in comparison to placebo
4 secondary outcomes
lipopolysaccharide
Time frame: baseline and 30 days after the intervention
C-reactive protein
Time frame: baseline and 30 days after the intervention
IL-6
Time frame: baseline and 30 days after the intervention
tumor necrosis factor-alpha
Time frame: baseline and 30 days after the intervention
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2025.
- Background: PubMed 23633524Pepino MY, Tiemann CD, Patterson BW, Wice BM, Klein S. Sucralose affects glycemic and hormonal responses to an oral glucose load. Diabetes Care. 2013 Sep;36(9):2530-5. doi: 10.2337/dc12-2221. Epub 2013 Apr 30.
- Background: PubMed 28613282Romo-Romo A, Aguilar-Salinas CA, Gomez-Diaz RA, Brito-Cordova GX, Gomez-Velasco DV, Lopez-Rocha MJ, Almeda-Valdes P. Non-Nutritive Sweeteners: Evidence on their Association with Metabolic Diseases and Potential Effects on Glucose Metabolism and Appetite. Rev Invest Clin. 2017 May-Jun;69(3):129-138. doi: 10.24875/ric.17002141.
- Background: PubMed 25231862Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N, Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal E, Elinav E. Artificial sweeteners induce glucose intolerance by altering the gut microbiota. Nature. 2014 Oct 9;514(7521):181-6. doi: 10.1038/nature13793. Epub 2014 Sep 17.
- Background: PubMed 30535090Romo-Romo A, Aguilar-Salinas CA, Brito-Cordova GX, Gomez-Diaz RA, Almeda-Valdes P. Sucralose decreases insulin sensitivity in healthy subjects: a randomized controlled trial. Am J Clin Nutr. 2018 Sep 1;108(3):485-491. doi: 10.1093/ajcn/nqy152.
- Background: PubMed 30005329Lertrit A, Srimachai S, Saetung S, Chanprasertyothin S, Chailurkit LO, Areevut C, Katekao P, Ongphiphadhanakul B, Sriphrapradang C. Effects of sucralose on insulin and glucagon-like peptide-1 secretion in healthy subjects: a randomized, double-blind, placebo-controlled trial. Nutrition. 2018 Nov;55-56:125-130. doi: 10.1016/j.nut.2018.04.001. Epub 2018 Apr 21.
- Background: PubMed 32130881Dalenberg JR, Patel BP, Denis R, Veldhuizen MG, Nakamura Y, Vinke PC, Luquet S, Small DM. Short-Term Consumption of Sucralose with, but Not without, Carbohydrate Impairs Neural and Metabolic Sensitivity to Sugar in Humans. Cell Metab. 2020 Mar 3;31(3):493-502.e7. doi: 10.1016/j.cmet.2020.01.014.
- Background: PubMed 35987213Suez J, Cohen Y, Valdes-Mas R, Mor U, Dori-Bachash M, Federici S, Zmora N, Leshem A, Heinemann M, Linevsky R, Zur M, Ben-Zeev Brik R, Bukimer A, Eliyahu-Miller S, Metz A, Fischbein R, Sharov O, Malitsky S, Itkin M, Stettner N, Harmelin A, Shapiro H, Stein-Thoeringer CK, Segal E, Elinav E. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022 Sep 1;185(18):3307-3328.e19. doi: 10.1016/j.cell.2022.07.016. Epub 2022 Aug 19.
- Background: PubMed 32284053Bueno-Hernandez N, Esquivel-Velazquez M, Alcantara-Suarez R, Gomez-Arauz AY, Espinosa-Flores AJ, de Leon-Barrera KL, Mendoza-Martinez VM, Sanchez Medina GA, Leon-Hernandez M, Ruiz-Barranco A, Escobedo G, Melendez G. Chronic sucralose consumption induces elevation of serum insulin in young healthy adults: a randomized, double blind, controlled trial. Nutr J. 2020 Apr 13;19(1):32. doi: 10.1186/s12937-020-00549-5.
- Derived from this study: PubMed 40907790Romo-Romo A, Sanchez-Tapia M, Lopez-Carrasco MG, Guillen-Pineda LE, Brito-Cordova GX, Martagon AJ, Granados-Portillo O, Walther G, Gomez-Perez FJ, Aguilar-Salinas CA, Tovar AR, Torres N, Almeda-Valdes P. Sucralose consumption modifies glucose homeostasis, gut microbiota, Curli protein, and related metabolites in healthy individuals: A randomized placebo-controlled, triple-blind trial. Clin Nutr ESPEN. 2025 Oct;69:733-744. doi: 10.1016/j.clnesp.2025.08.029. Epub 2025 Sep 2.
- Individual participant dataSharing planned: No
Related trials for GLP-1
RecruitingPhase 3
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Obesity or Overweight
RecruitingPhase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
Overweight or Obesity
RecruitingObservational study
Two-Year Weight Loss With GLP-1 Medications Compared With Sleeve Gastrectomy in Adults With Obesity
Obesity & Overweight
Not yet recruitingPhase 2
A Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SAL0150 Tablets in Subjects With Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM), Type 2 Diabetes
RecruitingPhase 3
A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)
Obesity, Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing sucralose in people with GLP-1 and Gut Microbiota, run by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
glucose (time frame: baseline and 30 days after the intervention). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06094894, which also lists 9 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2025.